Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00215826 | Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers | PHASE2 | COMPLETED | 10 | — | — | Nov 1, 2004 | Apr 1, 2006 | Apr 17, 2013 | 1 | Hong Kong |
Increased expression of genes known to be mediators of interferon response.
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | 650 IU |
| 2 | ACTIVE_COMPARATOR | 1300 IU |
| Name | Type | Description |
|---|---|---|
| Alferon LDO | DRUG | - |
Inclusion Criteria: 1. 18-80 years of age. 2. Asymptomatic with close contact within the last 5 days with a person known to have possible SARS (SARS RUI-2 (SARS Report under investigation), RUI-3, RUI-4) or probable SARS or confirmed SARS using the Centers for Disease Control and Prevention (CDC) S...